PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/625,124
Filing Date	07/23/2003
First Named Inventor	Dobrowolski, Steven
Art Unit	1645
Examiner Name	
Attorney Docket Number	2263

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CM		POMPONIO, RJ et al., Profound biotinidase deficiency caused by a point mutation that creates..., Human Molecular Genetics (1997), 6(5), 739-745.	
CM		COLE, H et al., Human Serum Biotinidase: cDNA Cloning, Sequence, and Characterization, J. Biol. Chem. (1994), 269(9), 6566-6570.	
CM		HEARD, Gregory et al., A Screening Method for Biotinidase Deficiency in Newborns, Clin. Chem. (1984), 30/1, 125-127.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.